Steven J Greco

Steven J. Greco, PhD, is a distinguished regenerative medicine leader based in Pinehurst, TX. As the Founder and Chief Operating Officer of PranaX Corporation, a cutting-edge biomedical research company in Houston, TX, Greco is at the forefront of pioneering new treatments to address age-related conditions and enhance overall health. With a strong academic foundation in biological sciences from Cornell University and a PhD in Stem Cell Biology from Rutgers University, Greco’s expertise lies in utilizing exosome biology to regenerate damaged tissues and organs, offering hope for rejuvenation and healing in aging populations. Greco’s career in regenerative medicine was shaped by his early work in biotech companies, where he gained invaluable experience in drug development, stem cell biology, and scientific research. His work at Rejenevie Therapeutics, where he co-founded the company and served as Chief Scientific Officer, and his role at Houston Healthspan Innovation Group laid the groundwork for his later success. Both companies were eventually acquired as subsidiaries of PranaX, which he founded in 2022. At PranaX, Greco applies his extensive research in Alzheimer’s disease, aging, and stem cell biology to develop new diagnostic tools, biomarkers, and therapies to combat the effects of aging and degenerative conditions. Over the past two decades, Steven J. Greco has made significant contributions to regenerative and translational medicine. His work has focused on advancing the use of stem cells in regenerative therapies, aiming to repair and regenerate damaged tissues and organs, particularly in aging and age-related diseases. Beyond his scientific research, Greco is deeply committed to educating the next scientists. He founded the Stem Cell Education Society to raise public awareness of stem cell applications, providing educational presentations to students, researchers, and industry professionals about the potential of regenerative medicine to improve health outcomes. Greco’s academic journey began at Cornell University, where he studied Biological Sciences with a concentration in Animal Physiology. This solid foundation in biology and human physiology set the stage for his future research in regenerative medicine. After completing his undergraduate degree, Greco pursued a Master's in Biomedical Sciences at Rutgers University, where he developed a strong interest in the intersection of chemistry, biology, and the body’s natural ability to regenerate and repair itself. In 2007, Steven earned his PhD in Stem Cell Biology from Rutgers Graduate School of Biomedical Sciences. At Rutgers, he worked as a Research Associate and Administrative Liaison in the Rameshwar Lab, where he contributed to cutting-edge research on stem cells, particularly in hematology and oncology. One of his key contributions was studying the interaction between mesenchymal stem cells and breast cancer in bone marrow, which helped advance the understanding of stem cell applications in cancer treatment. After completing his PhD, Steven’s career took off with a role as Vice President of Research and Development at Neurotez Inc., a company focused on drug discovery for Alzheimer’s disease. He then became Principal Scientist at the Cell Health Institute in Newark, NJ, where he worked on developing technologies to restore aging blood stem cell function. In collaboration with Rutgers University, his work at the Cell Health Institute helped advance stem cell research and regenerative therapies, cementing Greco’s role as a leader in the field. Greco’s expertise grew when he co-founded Rejenevie Therapeutics, serving as Director of Research and later as Chief Scientific Officer. At Rejenevie, Greco led research on restoring immune system function in aging individuals. His work at the company was pivotal in advancing regenerative treatments for age-related immune decline. Additionally, Greco contributed to Houston Healthspan Innovation Group, where he served as Chief Scientific Officer and played a key role in developing regenerative medical platforms to treat age-related diseases. In 2023, Steven J. Greco founded PranaX to advance stem cell and exosome therapies to regenerate aging and damaged tissues. Since its launch, PranaX has raised $20 million to support its innovative research and development efforts. Under Greco’s leadership, the company is making strides in developing therapies that can extend life expectancy and improve the quality of life for individuals impacted by aging and degenerative diseases. Greco is also a prolific inventor and holds numerous patents on stem cell biology and regenerative medicine. He has authored several publications on Alzheimer’s disease, aging, and stem cell therapies. His contributions to the scientific community have earned him numerous awards, including recognition from the New Jersey Commission on Science and Technology for his groundbreaking work in regenerative medicine. Through his leadership at PranaX, Steven J. Greco continues to push the boundaries of what is possible in regenerative medicine. His dedication to research, education, and innovation shapes the future of healthcare, offering new hope for individuals suffering from age-related health conditions. As PranaX continues to develop groundbreaking therapies, Greco’s work promises to improve people's lives worldwide, providing cutting-edge treatments that promote health and longevity in aging populations.